Navigation Links
Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem
Date:5/20/2009

May 1, 2009 in Groton, Connecticut

MORRISVILLE, N.C., May 20 /PRNewswire/ -- Asymchem Laboratories, Inc., a leading research-based contract manufacturer of APIs, intermediates and Drug Products to the pharmaceutical industry, with sites in the U.S. and China, is pleased to announce the recent award by Pfizer Inc. as the 2008 Top Intermediates CMO Award.

The award was presented at Pfizer's Groton, Connecticut R&D center on May 1, 2009. The award was the first in an annual series to be presented to high performing chemical intermediates suppliers. "A global network of high-quality chemical intermediate manufacturers is critical to enable Pfizer to create and sustain a competitive advantage," said Laurie Chipperfield, Director of API Strategic Sourcing.

Ed Kobelski, Global VP Supply Chain at Pfizer, presented the award to Dr. Hao Hong, CEO of Asymchem. "The steady growth of Asymchem's business at Pfizer is the result of their successful execution of each project, ability to achieve R&D speed targets, excellent customer service and high technical proficiency," stated Dr. Kobelski.

Pfizer uses a quantitative/qualitative supplier performance assessment process that combines performance data along with feedback from internal R&D and commercial project managers. Supplier excellence is judged on criteria including supplier value, delivery, account support, and compliance.

"I am very excited and honored to receive this award, and sincerely appreciate Pfizer's recognition of Asymchem's dedicated staff," states Dr Hao Hong, CEO of Asymchem. "By consistently delivering on time and within spec, we help push through projects that are time critical in the clinical arena. Our new Dunhua cGMP commercial production facility coming online later this year will further expand Asymchem's offerings."

The Asymchem headquarters, located in the RTP of North Carolina, coordinates highly technical chemical R&D/manufacturing facilities in China designed to provide integrated services for the pharmaceutical and biotech industries. With a diverse range of capabilities from the synthesis of sophisticated organic chemicals in the lab to commercial scale production of API's, Asymchem offers a comprehensive list of services for pharmaceutical customers. For more on Asymchem, please visit the website: www.asymchem.com.


'/>"/>
SOURCE Asymchem Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
6. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
7. WX Crowned Chemistry CRO of the Year by Pfizer
8. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
9. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... -- CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog ... Used combined in one project, multi-biometric solutions provide ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):